- Home
- CREV vs INDP Comparison
CREV vs INDP Comparison
Compare CREV & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- INDP
- Stock Information
- Founded
- CREV 2007
- INDP 2000
- Country
- CREV Ireland
- INDP United States
- Employees
- CREV N/A
- INDP N/A
- Industry
- CREV
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- INDP Health Care
- Exchange
- CREV Nasdaq
- INDP Nasdaq
- Market Cap
- CREV 6.0M
- INDP 6.0M
- IPO Year
- CREV N/A
- INDP N/A
- Fundamental
- Price
- CREV $4.61
- INDP $8.24
- Analyst Decision
- CREV
- INDP Strong Buy
- Analyst Count
- CREV 0
- INDP 2
- Target Price
- CREV N/A
- INDP $238.00
- AVG Volume (30 Days)
- CREV 447.3K
- INDP 9.4K
- Earning Date
- CREV 05-14-2025
- INDP 08-22-2025
- Dividend Yield
- CREV N/A
- INDP N/A
- EPS Growth
- CREV N/A
- INDP N/A
- EPS
- CREV N/A
- INDP N/A
- Revenue
- CREV $39,261,077.00
- INDP N/A
- Revenue This Year
- CREV $40.76
- INDP N/A
- Revenue Next Year
- CREV $86.18
- INDP N/A
- P/E Ratio
- CREV N/A
- INDP N/A
- Revenue Growth
- CREV 41.52
- INDP N/A
- 52 Week Low
- CREV $2.00
- INDP $6.65
- 52 Week High
- CREV $12.75
- INDP $58.24
- Technical
- Relative Strength Index (RSI)
- CREV 54.31
- INDP 43.38
- Support Level
- CREV $4.11
- INDP $6.65
- Resistance Level
- CREV $5.77
- INDP $7.84
- Average True Range (ATR)
- CREV 1.11
- INDP 0.78
- MACD
- CREV 0.02
- INDP -0.11
- Stochastic Oscillator
- CREV 24.26
- INDP 40.56
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.